Top pharmaceutical companies in conjunction with wealthy nations are to help prevent the spread of the swine flu virus in under developed nations.

Top Biotech Company AVI BioPharma (AVII), which develops RNA-based treatments for diseases like the Ebola virus, muscular dystrophy and the influenza virus has risen in stock price recently.

With advanced orders from the UK government for over 60 million doses of its swine flu vaccine, GlaxoSmithKline UK is preparing to sell £3bn worth of swine flu drugs this year. Glaxo is Britain’s biggest pharmaceutical supplier and has deals with world governments for its antiviral treatment Relenza, which can relieve swine flu symptoms. Is that good enough to consider this company as an investment option?